Labcorp has launched a groundbreaking blood test that could significantly accelerate Alzheimer’s diagnosis by measuring two key biomarkers: ptau-217 and beta amyloid 42. 

This first-of-its-kind immunoassay offers a faster, less invasive alternative to traditional brain scans and spinal fluid tests, with a reported 95% accuracy. 

The test can be performed with a simple blood draw at a doctor’s office or any of Labcorp’s 2,000+ U.S. locations. As the race to diagnose Alzheimer’s earlier intensifies, this innovation positions blood-based testing at the forefront of a new era in neurological care. 

It could be a game-changer for patients and doctors alike, enabling earlier access to life-changing treatments and giving families more time to plan for the future.